Literature DB >> 8883754

A randomized trial of 2 regimens for the administration of vaginal prostaglandins (gemeprost) for the induction of midtrimester abortion.

R J Armatage1, M J Luckas.   

Abstract

The most frequently used method for second trimester termination of pregnancy is administration of gemeprost (16, 16-dimethyl-trans delta 2-prostaglandin E1methyl ester) as a vaginal pessary. This provides a safe and effective method for achieving abortion. The current prescribing advice is to insert the pessaries into the posterior vaginal fornix every 3 hours. This study compares this to a 6-hourly regimen. The median abortion interval in the 6-hour group was shorter than the 3-hour group (15 versus 16 hours respectively) but the cumulative abortion rates were similar (98% in the 3-hour group and 91.8% in the 6-hour group). The 6-hour group required a significantly lower total dose of gemeprost to induce abortion. There was no difference in the rates of side-effects in the 2 groups but those receiving pessaries every 6 hours required less analgesia. This study finds no advantage in giving gemeprost every 3 hours.

Entities:  

Keywords:  Abortion Seekers; Abortion, Drug Induced--administraction and dosage; Abortion, Drug Induced--side effects; Abortion, Induced; Clinical Research; Clinical Trials; Comparative Studies; Demographic Factors; Developed Countries; Europe; Family Planning; Fertility Control, Postconception; Northern Europe; Population; Population Dynamics; Research Methodology; Research Report; Studies; Time Factors; United Kingdom

Mesh:

Substances:

Year:  1996        PMID: 8883754     DOI: 10.1111/j.1479-828x.1996.tb02714.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  1 in total

Review 1.  Medical methods for mid-trimester termination of pregnancy.

Authors:  Hajo Wildschut; Marieke I Both; Suzanne Medema; Eeke Thomee; Mark F Wildhagen; Nathalie Kapp
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.